Micro Labs, based in Bengaluru, announced the launch of Trisopt, the world’s first fixed-dose combination (FDC) to include Brimonidine, Timolol, and Brinzolamide in an ophthalmic suspension, designed specifically for the management of glaucoma.
The drug is manufactured within Micro Labs' cutting-edge facility located in Sikkim.
In India, glaucoma continues to affect countless lives as one of the leading causes of irreversible blindness. The burden on glaucoma patients is often intensified by the necessity of multiple eye drops to prevent disease progression, and the ensuing challenge of managing the associated high therapy costs.
At the recent annual conference of the All-India Ophthalmological Society, convened in Kochi, experts convened to deliberate on the unique difficulties encountered by glaucoma patients, particularly those managing multi-drug regimens.
Trisopt arrives as a game-changing solution, heralding the era of triple drug fixed-dose combinations for glaucoma management in India. This innovation not only augments the efficacy and safety for patients whose condition remains uncontrolled under a two-drug regimen but also addresses the intricate challenges posed by the existing therapy landscape.
*Stay in the loop and make sure not to miss real-time breaking news about ophthalmology. Join our community by subscribing to OBN newsletter now.